SCHEMBL4306191

SCHEMBL4306191

C[Si](C)(C)C#Cc1ccc(OC(F)F)c(Cl)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.40
MEN1 O00255 11/20 0.40
KMT2A Q03164 11/20 0.40
ALDH1A1 P00352 6/20 0.40
HTT P42858 8/20 0.40
LMNA P02545 7/20 0.40
SMN1; SMN2 Q16637 5/20 0.38
RAB9A P51151 4/20 0.38
NPC1 O15118 3/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
TP53 P04637 1/20 0.36
HTR1E P28566 1/20 0.36
S1PR3 Q99500 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NPSR1 Q6W5P4 2/20 0.35
POLB P06746 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GRM2 Q14416 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313333 0.83 BACE1 (0.38)
SCHEMBL4309746 0.81 LMNA (0.32) MEN1KMT2AHTTLMNASMN1; SMN2
SCHEMBL4308442 0.80 GABRA1 (0.31) MEN1KMT2AHTTLMNA
SCHEMBL4317680 0.79 GABRA1 (0.36) MAPTMEN1KMT2AHTTLMNA
SCHEMBL27801224 0.78 LOX (0.32) HTTHPGD
SCHEMBL16959800 0.76 MAPT (0.41) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL28783777 0.76 MAPT (0.41) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL4315907 0.76 MAPT (0.41) MAPTMEN1KMT2AALDH1A1HTT
SCHEMBL10163925 0.75 PYGL (0.40) TP53TDP1
SCHEMBL26262204 0.74 GABRA1 (0.40) MEN1KMT2ARAB9ANPC1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137161-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2009-12-30 EP disclosed
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS WYETH (US) 2009-02-12 US disclosed
WO-2008115552-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ß-SECRETASE INHIBITORS WYETH (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042964-A1 AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5-PHENYLIMIDAZOLONE COMPOUNDS AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP MAPT 17/4885MEN1 3838/4885KMT2A 2465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.